---
title: "Bayer Seeks Market Authorization in Japan for Heart Failure Treatment"
date: "2025-02-14 17:21:14"
summary: "Bayer filed a marketing authorization application in Japan for its finerenone treatment for adult patients with chronic heart failure. The application was filed with the Ministry of Health, Labour, and Welfare based on positive data from the phase 3 Finearts-HF study under the Moonraker phase 3 clinical program, according to..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Bayer filed a marketing authorization application in Japan for its finerenone treatment for adult patients with chronic heart failure.

The application was filed with the Ministry of Health, Labour, and Welfare based on positive data from the phase 3 Finearts-HF study under the Moonraker phase 3 clinical program, according to a Friday release.

The pharmaceutical company added that applications for finerenone are also under review in the US, the European Union, and China.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250214:G2467975:0/)
